Enigma and Tecan Expand OEM Pact to Develop High-Throughput MDx Platform for Third Party
January 13, 2011
Enigma and Tecan Expand OEM Pact to Develop High-Throughput MDx Platform for Third Party
The agreement builds upon an existing OEM pact between the companies under which Tecan is manufacturing and will help market Enigma's forthcoming Enigma ML testing device for the point-of-care and low-complexity laboratory markets.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GSK to Market Enigma Diagnostics' POC Respiratory Disease Tests Under New Pact
August 10, 2011 / PCR Insider - Enigma Dx Begins Clinical Trials for Flu Test on Integrated MDx Platform
April 14, 2011 / PCR Insider - Tecan Licenses Molecular Dx IP from Enigma
January 11, 2011 / GenomeWeb Daily News - Enigma Diagnostics Taps Tecan to Make and Market Forthcoming POC Molecular Dx Platform
February 11, 2010 / PCR Insider - Enigma Wraps Up EU-Funded Consortium to Develop Seasonal Flu MDx
July 19, 2011 / PCR Insider